apoptosis and reversion of the epithelial-mesenchymal transition (EMT). Cpd188 delayed in vivo tumor growth alone and in combination with radiation and TMZ. We also confirmed the radiosensitizing effect of Cpd188 in GBL28 cells, which were originated from a patient with a high level of STAT3 expression and unmethylated MGMT. Targeting STAT3 using Cpd188 could be a viable therapeutic approach for improving the outcome of current standard therapy in glioblastoma patients with high p-STAT3 expression.
Introduction
Glioblastoma is the most common malignant primary brain tumor in adults, and its extremely poor prognosis is because of its high degree of treatment resistance [1] . The EORTC/ NCIC phase III trial showed that the postoperative addition of temozolomide (TMZ) to radiation resulted in a significant survival benefit for glioblastoma patients. Nevertheless, the median survival time did not exceed 15 months [2] . Preclinical studies and clinical trials for diverse molecular targeting drugs have been performed to increase the therapeutic efficacy of current standard therapy [3] . Recently, Prados et al. suggested applying combination therapy for multiple actionable targets to overcome the limited efficacy of single targeted therapy in the face of tumor heterogeneity [4] .
The signal transducers and activators of transcription (STATs) are a family of transcription factors that are activated by membrane-bound receptors and that subsequently translocate to the nucleus to promote the expression of a variety of cell survival, differentiation, and proliferation Abstract Even with aggressive treatment involving radiation therapy plus temozolomide (TMZ), the prognosis for glioblastoma remains poor. We investigated the potential for targeting signal transducer and activator of transcription-3 (STAT3) to improve the therapeutic outcome in glioblastoma. We evaluated the preclinical potential of a STAT3 inhibitor, Cpd188, combined with temozolomide and radiation using in vitro assays with two established glioblastoma cell lines (U251 and U87) and two patientderived glioblastoma cell lines (GBL12 and GBL28) as well as in vivo studies with nude mice bearing intracranial U251 xenografts. Cpd188 potentiated the radiosensitizing effect of TMZ in U251 cells, which have high p-STAT3 expression levels. The enhanced radiosensitizing effects of TMZ were associated with impaired DNA damage repair, control, DMSO or Cpd188 (10 μM) with or without TMZ (25 μM).
Clonogenic assay
A specified number of cells were seeded into each well of six-well culture plates and then treated with or without temozolomide and Cpd188 for 24 h. Subsequent procedures were performed as previously described [20] . Survival data were fit to a linear-quadratic model using Kaleidagraph version 3.51 (Synergy Software, Reading, PA, USA). The sensitizer enhancement ratio (SER) was calculated as the ratio of the isoeffective dose at surviving fractions of 0.5 and 0.05 in the absence of the drugs relative to that in the presence of the drugs.
Western blot analysis and immunocytochemistry
Immunoblot analysis was performed as previously described [20] . Primary antibodies for p-Akt (Ser473; #4060), p-ERK (Thr202/Tyr204; #4376), caspase-3 (#9665), matrix metalloproteinase (MMP)-2 (#13132), E-cadherin (#3195), EphA2 (#6997, Cell Signaling Technology, I nc., Danvers, MA, USA), and total STAT3 (sc-482, Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used at 1:1000 dilutions. Antibodies against p-STAT3 (Tyr705; sc-7993-R), vascular endothelial growth factor (VEGF; sc-507), and β-actin (sc-47778, Santa Cruz Biotechnology) were used at dilutions of 1:500 and 1:5000, respectively. For the immunocytochemistry, the cells were seeded on a chamber slide; fixed with 4 % paraformaldehyde; probed with antibodies for γ-H2AX, 53BP1 (#6209, Cell Signaling Technology) and VEGF; and incubated with the Alexa Fluor 488 secondary antibody (A-11008, Molecular Probes, Eugene, OR, USA). The nuclei were counterstained with DAPI (4′, 6-diamidino-2-phenylindole). All antibodies are originated from rabbits, except for β-actin (from mouse).
Apoptosis
Caspase-3/7 activity was measured as per the manufacturer's instructions (Invitrogen, Life Technologies, Carlsbad, CA, USA). Cells were stained with annexin V-FITC/PI according to the manufacturer's instructions (BD Biosciences, San Jose, CA, USA), and they were analyzed with a fluorescence microscope (Carl Zeiss, Goettingen, Germany).
Modified boyden chamber assay
A transwell system (Corning, Rochester, NY, USA), which allows cells to migrate through 8-μm pores in polycarbonate membranes, was used. Inserts containing cells were placed in 24-well plates (Corning) in starvation medium. After genes [5] . I n particular, STAT3 is a key candidate in the malignant progression of glioma, and its aberrant activation has been a poor prognostic factor for survival in glioma patients [6] [7] [8] . Phosphorylated STAT3 (p-STAT3) causes transcriptional activation of downstream genes involved in various processes, such as cell proliferation, differentiation, survival, and angiogenesis. I n this way, STAT3 is a convergence point for many signaling pathways, and it plays an important role in oncogenesis. Efforts are ongoing to develop anticancer drugs that target STAT3 [9] [10] [11] . A number of potential drugs inhibiting STAT3 activity have been investigated in malignant gliomas [12] [13] [14] [15] [16] [17] . Furthermore, STAT3 inhibition seems to increase TMZ efficacy by downregulating O 6 -methyl-guanine methyl transferase gene (MGMT) expression in TMZ-resistant glioblastoma cell lines [18] . However, their work did not cover the effect of radiation on combined therapy with STAT3 inhibitor and temozolomide. Cpd188, a small molecule STAT3 inhibitor, can cross the blood-brain barrier and inhibit STAT3 Y705 phosphorylation by targeting the STAT3 SH2 domain peptide-binding pocket [19] .
In this study, we investigated the effects of the combination of Cpd188 with radiation and TMZ in vitro and in vivo and showed that STAT3 inhibition could be a viable approach for increasing the efficacy of TMZ combined with radiation against an activated STAT3 subtype of glioblastoma.
Materials and methods

Cell culture
Human glioblastoma cell lines, U251 and U87, and normal human astrocytes (NHA) were obtained from the American Type Culture Collection. I RB-approved, patientderived glioblastoma cell lines, GBL12 and GBL28, were provided by Dr. Sun Ha Paek (Seoul National University, Republic of Korea). To assess whether Cpd188 has a cytotoxic effect on NHA in the concentration of 10 μM, we examined the SF2 of NHA after treating inhibitors. Cells were maintained and cultured according to standard techniques at 37 °C in 5 % (v/v) CO 2 using Dulbecco's modified Eagle's medium.
Pharmacologic inhibitors
Temozolomide (Schering-Plough, Kenilworth, NJ, USA) was stored as a 125-mM solution in dimethyl sulfoxide (DMSO; Sigma-Aldrich, St, Louis, MO, USA). The STAT3 inhibitor, 4-((3-(carboxymethylsulfanyl)-4-hydroxy-1-naphthyl)sulfamoyl)benzoic acid (Cpd188), was purchased from Calbiochem (Darmstadt, Germany). On the first treatment day, the media were replaced with vehicle minutes after injection, the mice were anesthetized with 1-2 % isoflurane. Bioluminescence images were acquired using the IVIS Imaging System 100 series (Xenogen Corporation, Alameda, CA, USA), and the peak luminescence signals were recorded.
Immunohistochemistry
Mouse brain tissue was frozen in liquid isopentane that had been chilled on dry ice and stored with embedding matrix at −80 °C. Then, the tissue was sliced into 10-µm sections in a cryostat (Cryocut 1800, Reichert-Jung) which was cooled to −20 °C. The sections were fixed with formaldehyde, and the slides were incubated for 18 h with primary antibodies for HIF-1α (Cell Signaling Technology, Inc), VEGF, or CD31 (Santa Cruz Biotechnology). Secondary FI TC antirabbit antibody (Molecular Probes, Eugene, OR, USA) was applied to the tissues and incubated for 2 h. DAPI nuclear counterstain (1 μg/mL) was applied for 5 min.
Statistical analysis
The results are expressed as the means ± standard deviation (SD) of the three independent experiments. Data from these experiments were analyzed using the Student's t test (SPSS v15.0 software). The Kaplan-Meier survival curves were constructed using GraphPad Prism 6.0 software (GraphPad Software, San Diego, CA, USA), and a log-rank test was used to examine the differences between groups.
Results
In vitro radiosensitizing effect
The U251 and GBL28 cell lines had high p-STAT3 expression levels in a panel of glioblastoma cell lines (Fig. 1a) . Pretreatment with Cpd188 significantly down-regulated p-STAT3 expression (Fig. 1b) . U251 cells, which have high p-STAT3 expression showed a high degree of radiosensitization in response to Cpd188 plus TMZ (SER 0.5 , 1.43), whereas U87 cells with low p-STAT3 expression had less radiosensitization (SER 0.5 , 1.34) (Fig. 1c) . Radiationinduced cell death with 6 Gy was significantly enhanced in the combination treatment group compared to the singledrug groups for U251 cells (p < 0.01 for TMZ and p < 0.01 for Cpd188) based on unpaired t test. For U87 cells, however, the combination treatment did not potentiate radiationinduced cell death with 6 Gy compared to the single-drug treatment (p = 0.13 for TMZ, p = 0.06 for Cpd188). Cpd188 did not affect surviving fraction in normal human astrocytes ( Supplementary Fig. S1 ).
24 h, inserts were fixed in methanol and stained with 1 % crystal violet solution. The invasion was calculated using quantitative analysis of the optic density at 560 nm.
Wound healing assay
Cells were grown to confluence in six-well plates (SonicSeal Slide; Nalge Nunc, Rochester, NY, USA) and starved as described above. Using a 1-mL pipette tip, a line was scratched in each hemisphere of the well, and the medium was replaced with starvation medium. Images were taken of the intersections for the linear cell wound and each grid line. The migration was estimated from the distance that the cells moved, as determined microscopically.
Vasculogenic mimicry formation assay
The vasculogenic mimicry (VM) formation assay was performed using a commercial Matrigel assay kit (BD Biosciences). ECM Matrigel (200 μL) was added to each well and incubated at 37 °C for 2 h. Cells were treated and seeded onto the coated plate. After 24 h, VM formation was assessed using an inverted microscope.
In vivo tumor model
U251 cells had been modified to express a luciferase reporter (Promega, Fitchburg, WI , USA) to track tumor growth. Human glioblastoma xenografts were established by injecting 3 × 10 5 cells intracranially into the right caudate-putamen of 6-to 8-week-old male BALB/c athymic nude mice (Orient Bio Inc, Sungnam, Korea). Mice were randomized into eight groups of five animals per group on day 14 after injection; control, Cpd188 only, TMZ only, TMZ combined with Cpd188, irradiation only, Cpd188 combined with radiation, TMZ combined with radiation, and TMZ combined with Cpd188 and radiation. The following drug treatments started on day 15; TMZ was administered orally in PBS at a dose of 25 mg/kg three times weekly for 3 weeks and Cpd188 was dissolved in PBS and administered intraperitoneally at a dose of 20 mg/kg three times weekly for 3 weeks. When Cpd188 and TMZ were given in combination, TMZ was given 30 min after Cpd188. In control group, PBS only was administered orally or injected intraperitoneally. Starting on day 22 post-injection, mice were irradiated with a total of 9 Gy in three fractions per week using a 6 MeV electron beam.
Bioluminescence imaging
Beginning on day 14 post-injection, the mice were intraperitoneally injected with 150 mg/kg d-luciferin. Fifteen combination of Cpd188 and radiation ± TMZ significantly impaired VM formation and down-regulated VEGF, MMP-2, and EphA2 expression, while up-regulating E-cadherin expression.
In vivo radiosensitizing effect
On day 35, the last day that three nude mice from each group were alive, the median bioluminescence values indicated a sixfold decrease in the volume for Cpd188 alone (p = 0.001), 20-fold decrease for TMZ alone (p = 0.008), 43-fold decrease for TMZ combined with Cpd188 (p = 0.001), threefold decrease for irradiation alone (p = 0.005), 11-fold decrease for Cpd188 combined with radiation (p = 0.001), 28-fold decrease for
DNA damage repair and apoptosis
Effect of Cpd188 on the repair of radiation-induced DNA double-strand breaks was tested by immunofluorescence. Cpd188 treatment led to persistent gamma H2AX and 53BP foci formation after radiation (p < 0.01) (Fig. 2a) . I t also generated late-apoptotic cells (Fig. 2b) and increased the cleaved caspase-3 expression and caspase-3/7 activity within 24 h after treatment in U251 cells (Fig. 2c, p < 0.01) .
Reversion of EMT features
The combination of Cpd188 and radiation ± TMZ markedly inhibited the invasion and migration of U251 glioblastoma cells (Fig. 3a, b , p < 0.05). As shown in Fig. 3c , the Fig. 1 p- 
Effect on the tumor microenvironment
Cpd188 decreased the expression of CD31, which is a marker of endothelial proliferation, as well as of HIF-1α and VEGF. The CD31, VEGF, and HIF-1α staining results for cells that were only treated with Cpd188 were comparable to those that underwent combined treatment (Supplementary Fig. 2 ).
Clonogenic survival of patient-derived glioblastoma cells that have unmethylated MGMT
As U251 and U87 cell lines are known to have a methylated MGMT promoter [21] , we wanted to test the patient-derived cells that have unmethylated MGMT. GBL12/28 cell lines are TMZ combined with radiation (p = 0.008), and 83-fold decrease for TMZ combined with Cpd188 and radiation (p = 0.001) relative to the control group (Fig. 4a) . The median bioluminescence value in the triple treatment decreased significantly compared to those of TMZ combined with Cpd188 (p = 0.041), TMZ combined with radiation (p = 0.037) and Cpd188 combined with radiation (p = 0.022). As shown in Fig. 4b , survival in the triple treatment group (radiation plus TMZ and Cpd188) was significantly longer than in the control (p = 0.003) and radiation alone groups (p = 0.007). However, it was not significantly different compared to TMZ combined with Cpd188 group (p = 0.937), TMZ combined with radiation group (p = 0.937) and Cpd188 combined with radiation group (p = 0.426). (Fig. 5a, b) . For GBL28 cells, radiation-induced cell death with 6 Gy had a trend for enhancement in the combined treatment group compared to the single-drug groups of GBL28 cells (p = 0.09 for TMZ and p = 0.07 for Cpd188). Figure 5c shows magnetic resonance images (MRI) for each originated from the patients with glioblastoma with unmethylated MGMT. While GBL12 cells, which have low p-STAT3 expression, showed less radiosensitization with Cpd188 plus TMZ, GBL28 cells, which have high p-STAT3 expression, showed a high degree of radiosensitization with Cpd188 plus 
Discussion
We observed a link between STAT3 and DNA damage repair. Barry et al. also reported that STAT3 is necessary for DNA damage repair via the ATM-Chk1/2 pathways in mouse embryonic fibroblasts [22] . Another study suggested that the cdk5-STAT3 pathway reduces DNA damage in response to topoisomerase I inhibition, via activation of Eme1, in human colorectal cells [23] . Glioblastoma is highly resistant to apoptosis, and STAT3 acts as a suppressor of apoptosis in a number of cancer cell lines [24] . Inhibition of STAT3 delayed tumor growth and improved animal survival by inducing apoptosis and enhancing immunemediated cytotoxicity in tumor cells [25] .
Highly invasive characteristics are critical to glioblastoma, and they are considered a major therapeutic obstacle for glioblastoma [26] . We showed that Cpd188 inhibited the invasion and migration of U251 cells in this study. Li et al. showed that radiation promoted the invasion of A549 cells as well as induced STAT3 phosphorylation, promoting its nuclear localization; inhibition of STAT3 phosphorylation suppressed the radiation-induced expression of MMP-2 and invasion [27] . VM is as the process whereby non-endothelial, tumor cell-lined, microvascular channels are formed, and traditional anti-vascular therapies that target endothelial cells have no significant effects on malignant tumors with VM [28] . Radiotherapy activates various radiation response genes and cytokines as well as alters the tumor microenvironment, increasing the invasion and metastasis of any surviving tumor cells. These properties enhance therapeutic resistance and tumor repopulation [29] .
We observed that Cpd188 selectively sensitized glioblastoma cells without affecting normal human astrocytes. STAT3 is not essential for the survival of untransformed cells, but it is indispensable for many different tumor cells [30] , providing a sound rationale for targeting STAT3. We also confirmed that Cpd188 specifically downregulated phosphorylated STAT3 without change of the expression level of total STAT3 (Supplementary Fig. 3) .
The EORTC/NCIC trial revealed that the methylation status of the MGMT promoter was the strongest predictor that a patient would benefit from the addition of TMZ [31] . The therapeutic benefit of TMZ in those with an unmethylated MGMT promoter is remarkably limited [32] . Kohsaka et al. suggested that STAT3 inhibition could overcome TMZ resistance in glioblastoma by down-regulating MGMT methylation [18] . We observed that Cpd188 enhanced the radiosensitizing effect of TMZ in a patient-derived GBL28 cell line that had unmethylated MGMT. This result suggests that the combination of Cpd188 and TMZ could be a useful approach for treating patients with unmethylated and methylated MGMT.
Taken together, our data suggest that targeting STAT3 has the potential to improve the outcome of current standard therapy for glioblastoma in patients with tumors that have high p-STAT3 expression.
